Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors

Cyanidin-3-o-β-Glucoside Induces Megakaryocyte Apoptosis via PI3K/Akt- and MAPKs-Mediated Inhibition of NF-κB Signalling

(2018) Fuli Ya et al.   THROMBOSIS AND HAEMOSTASIS

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

(2018) Ian W. Flinn et al.   BLOOD

Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma

(2017) P. Penttilä et al.   EUROPEAN JOURNAL OF CANCER

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience

(2017) Takeo Fujii et al.   INVESTIGATIONAL NEW DRUGS

Regulation of mitochondrial biogenesis in erythropoiesis by mTORC1-mediated protein translation

(2017) Xin Liu et al.   NATURE CELL BIOLOGY

Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis.

(2017) Shanthi Sivendran et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy

(2016) H. S. Rugo et al.   ANNALS OF ONCOLOGY

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

(2016) B. L. Lampson et al.   BLOOD

A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)

(2016) Vicky Makker et al.   CANCER

The anti-apoptotic Bcl-2 family protein A1/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK/STAT signaling

(2016) J Vier et al.   Cell Death & Disease

AKT/GSK3β signaling pathway is critically involved in human pluripotent stem cell survival

(2016) Leonardo Romorini et al.   Scientific Reports

The Roles of mTOR Complexes in Lipid Metabolism

(2015) Alexandre Caron et al.   Annual Review of Nutrition

Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

(2015) E Geuna et al.   BRITISH JOURNAL OF CANCER

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma

(2015) J. R. Brown et al.   CLINICAL CANCER RESEARCH

Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

(2015)   CLINICAL CANCER RESEARCH

The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab

(2015) N. L. Busaidy et al.   ONCOLOGIST

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia

(2014) J. R. Brown et al.   BLOOD

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma

(2014) I. W. Flinn et al.   BLOOD

Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms

(2014) Ignacio Duran et al.   Expert Opinion On Drug Safety

Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer

(2014) Daliah Tsoref et al.   GYNECOLOGIC ONCOLOGY

Computer-Aided Targeting of the PI3K/Akt/mTOR Pathway: Toxicity Reduction and Therapeutic Opportunities

(2014) Tan Li et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Tilting the Balance of Dose Modification for Oral Anticancer Drugs?

(2014) Philippe L. Bedard et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of Mucositis in Patients Treated With Temsirolimus-Based Regimens and Correlation to Treatment Response

(2014) X. Liu et al.   ONCOLOGIST

A critical role for mTORC1 in erythropoiesis and anemia

(2014) Zachary A Knight et al.   eLife

A Central Role for mTOR in Lipid Homeostasis

(2013) Dudley W. Lamming et al.   Cell Metabolism

PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

(2013) David G. Winkler et al.   CHEMISTRY & BIOLOGY

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

(2013) G. I. Shapiro et al.   CLINICAL CANCER RESEARCH

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

(2013) Ningshu Liu et al.   MOLECULAR CANCER THERAPEUTICS

A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients

(2013) Fabiana Martins et al.   ORAL ONCOLOGY

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

(2012) B. Markman et al.   ANNALS OF ONCOLOGY

Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome

(2012) Donnette A. Dabydeen et al.   EUROPEAN JOURNAL OF CANCER

PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis

(2012) Simon M. Schultze et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

(2012) C. Renner et al.   HAEMATOLOGICA

Infection with Anaplasma phagocytophilum Activates the Phosphatidylinositol 3-Kinase/Akt and NF-κB Survival Pathways in Neutrophil Granulocytes

(2012) Arup Sarkar et al.   INFECTION AND IMMUNITY

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

(2012) Naifa L. Busaidy et al.   JOURNAL OF CLINICAL ONCOLOGY

Functional Redundancy of Class I Phosphoinositide 3-Kinase (PI3K) Isoforms in Signaling Growth Factor-Mediated Human Neutrophil Survival

(2012) Jatinder K. Juss et al.   PLoS One

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

(2011) Andrew X. Zhu et al.   CANCER

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors

(2011) Yoshitaka Seki et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis

(2011) Cristina Gomez-Fernandez et al.   EUROPEAN JOURNAL OF CANCER

Cooperation between both Wnt/ -catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion

(2011) J. M. Perry et al.   GENES & DEVELOPMENT

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

(2011) Amit M. Oza et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia

(2011) E J Gallagher et al.   ONCOGENE

Clinical presentation and management of mTOR inhibitor-associated stomatitis

(2011) Marcio Augusto de Oliveira et al.   ORAL ONCOLOGY

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27Kip1

(2010) Takafumi Nakao et al.   CELL CYCLE

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

(2010) A. Tarhini et al.   CLINICAL CANCER RESEARCH

Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue

(2010) V. P. Houde et al.   DIABETES

Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke–induced pulmonary injury and emphysema

(2010) Toshinori Yoshida et al.   NATURE MEDICINE

Neutrophil spontaneous death is mediated by down-regulation of autocrine signaling through GPCR, PI3K , ROS, and actin

(2010) Y. Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeted deletion of tumor suppressor PTEN augments neutrophil function and enhances host defense in neutropenia-associated pneumonia

(2009) Y. Li et al.   BLOOD

Comprehensive lung injury pathology induced by mTOR inhibitors

(2009) Guadalupe Aparicio et al.   Clinical & Translational Oncology

Drug-Induced Thrombocytopenia

(2009) Karen K. Swisher et al.   DRUG SAFETY

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

(2009) Susan L. Ellard et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy

(2008) Lindsey N. Jackson et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

(2008) J. Bellmunt et al.   ANNALS OF ONCOLOGY

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

(2008) D. A. Rizzieri et al.   CLINICAL CANCER RESEARCH

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

(2008) Monica M. Mita et al.   JOURNAL OF CLINICAL ONCOLOGY